Art. 71 Directive (EU) 2001/83

In forcesince 26 Jan 2007cited 18×
1.

Medicinal products shall be subject to medical prescription where they:

are likely to present a danger either directly or indirectly, even when used correctly, if utilized without medical supervision, or

are frequently and to a very wide extent used incorrectly, and as a result are likely to present a direct or indirect danger to human health, or

contain substances or preparations thereof, the activity and/or adverse reactions of which require further investigation, or

are normally prescribed by a doctor to be administered parenterally.

2.

Where Member States provide for the sub-category of medicinal products subject to special medical prescription, they shall take account of the following factors:

the medicinal product contains, in a non-exempt quantity, a substance classified as a narcotic or a psychotropic substance within the meaning of the international conventions in force, such as the United Nations Conventions of 1961 and 1971, or

the medicinal product is likely, if incorrectly used, to present a substantial risk of medicinal abuse, to lead to addiction or be misused for illegal purposes, or

the medicinal product contains a substance which, by reason of its novelty or properties, could be considered as belonging to the group envisaged in the second indent as a precautionary measure.

3.

Where Member States provide for the sub-category of medicinal products subject to restricted prescription, they shall take account of the following factors:

the medicinal product, because of its pharmaceutical characteristics or novelty or in the interests of public health, is reserved for treatments which can only be followed in a hospital environment,

the medicinal product is used in the treatment of conditions which must be diagnosed in a hospital environment or in institutions with adequate diagnostic facilities, although administration and follow-up may be carried out elsewhere, or

the medicinal product is intended for outpatients but its use may produce very serious adverse reactions requiring a prescription drawn up as required by a specialist and special supervision throughout the treatment.

4.

A competent authority may waive application of paragraphs 1, 2 and 3 having regard to:

(a)

the maximum single dose, the maximum daily dose, the strength, the pharmaceutical form, certain types of packaging; and/or

(b)

other circumstances of use which it has specified.

5.

If a competent authority does not designate medicinal products into sub-categories referred to in Article 70(2), it shall nevertheless take into account the criteria referred to in paragraphs 2 and 3 of this Article in determining whether any medicinal product shall be classified as a prescription-only medicine.

The 10 that are cited most themselves, of 18.

  • Judgment of the Court of 11 December 2003. Deutscher Apothekerverband eV v 0800 DocMorris NV and Jacques Waterval.Decision

    First, the Community Code provides, in Title VI, ‘Classification of Medicinal Products’, that when the competent authorities of the Member States grant a marketing authorisation for a medicinal product they must specify its …

    11 Dec 2003 · 62001CJ0322

  • Judgment of the Court (Third Chamber) of 11 June 2020. ratiopharm GmbH v Novartis Consumer Health GmbH.Decision

    Regarding medicinal products subject to medical prescription, the criteria which they meet, as set out in Article 71(1) of Directive 2001/83, reflect the idea that, in view of the dangers of their use or the uncertainty around their …

    11 Jun 2020 · 62018CJ0786

  • Directive (EU) 2011/2411Law

    … които се изисква специално лекарско предписание, предвидено в член 71, параграф 2 от Директива 2001/83/ЕО.

  • Judgment of the Court (Fifth Chamber) of 18 September 2019. VIPA Kereskedelmi és Szolgáltató Kft. v Országos Gyógyszerészeti és Élelmezés-egDecision

    The referring court therefore considers it necessary to ascertain whether the prescriptions for a named patient referred to in Article 11(1) of Directive 2011/24 refer only to prescriptions issued for a specific patient or whether, in …

    18 Sep 2019 · 62018CJ0222

  • Judgment of the Court (Fifth Chamber) of 5 February 2015. Miguel M. and Others.Decision

    … som let kan benyttes eller udskilles ved hjælp af let anvendelige eller økonomisk fordelagtige midler, fastsætter artikel 71, stk. 1, andet led, i direktiv 2001/83, således som Generalbundesanwalt beim Bundesgerichtshof, den …

    5 Feb 2015 · 62013CJ0627

  • Opinion of Advocate General Szpunar delivered on 20 May 2021. Pharma Expressz Szolgáltató és Kereskedelmi Kft v Országos Gyógyszerészeti és Decision

    In those circumstances, by decision of 10 March 2020, received at the Court on 7 April 2020, the Fővárosi Törvényszék (formerly the Fővárosi Közigazgatási és Munkaügyi Bíróság) (Budapest High Court, formerly Budapest …

    20 May 2021 · 62020CC0178

  • Opinion of Advocate General Bot delivered on 12 June 2019. VIPA Kereskedelmi és Szolgáltató Kft. v Országos Gyógyszerészeti és Élelmezés-egéDecision

    The referring court states that it has difficulty in determining whether the Hungarian legislation in question is compatible with the concept of ‘prescription’ as defined in EU law and with the rule that medical prescriptions should be …

    12 Jun 2019 · 62018CC0222

  • Judgment of the Court (Third Chamber) of 5 May 2011. MSD Sharp & Dohme GmbH v Merckle GmbH.Decision

    According to Article 71(1) of that directive: ‘Medicinal products shall be subject to medical prescription where they: are likely to present a danger either directly or indirectly, even when used correctly, if utilised without medical …

    5 May 2011 · 62009CJ0316

  • BGH, Urteil vom 8. Januar 2015 - I ZR 123/13Decision

    … Dabei kommt im Streitfall hinzu, dass durch § 48 AMG der Titel VI und insbesondere Art. 71 der Richtlinie 2001/83/EG zur Schaffung eines Gemeinschaftskodexes für Humanarzneimittel in das deutsche Recht umgesetzt wird (vgl. Rehmann, …

    8 Jan 2015 · KORE313842015

  • Judgment of the Court (Fourth Chamber) of 8 July 2021. Pharma Expressz Szolgáltató és Kereskedelmi Kft v Országos Gyógyszerészeti és ÉlelmezDecisioninterprets

    In those circumstances the Fővárosi Törvényszék (Budapest High Court) decided to stay the proceedings and to refer the following questions to the Court of Justice for a preliminary ruling: Does an obligation flow from Articles 70 to …

    8 Jul 2021 · 62020CJ0178